Alteplase for the treatment of central venous catheter occlusion in children: Results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study)

Journal of Vascular and Interventional Radiology

Volumn 17, Issue 11 I, 2006, Pages 1745-1751

  Blaney, Martha ^a   Shen, Violet ^b   Kerner, John A ^c   Jacobs, Brian R ^e   Gray, Sarah ^a   Armfield, Jennifer ^a   Semba, Charles P ^a,d  

^a GENENTECH INC   (United States)

^b CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^c LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; CATHFLO ACTIVASE;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CATHETER OCCLUSION; CENTRAL VENOUS CATHETER; CHILD; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFECT; DRUG EFFICACY; DRUG INSTILLATION; DRUG SAFETY; EMBOLISM; EVALUATION; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTHESIS FAILURE; RUPTURE OF CATHETER LUMEN; SEPSIS; THROMBOSIS;

ADOLESCENT; CATHETERIZATION, CENTRAL VENOUS; CHILD; CHILD, PRESCHOOL; EQUIPMENT FAILURE; FIBRINOLYTIC AGENTS; HUMANS; INFANT; PATIENT SELECTION; PROSPECTIVE STUDIES; SAFETY; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33751277433     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000241542.71063.83     Document Type: Article

References (15)

1. Stovroff M, Teague WG. Intravenous access in infants and children. Pediatr Clin North Am 1998; 45:1373-1393.
2. Shen V, Li X, Murdock M, et al. Recombinant tissue plasminogen activator (Alteplase) for restoration of function to occluded central venous catheters in pediatric patients. J Pediatr Oncol 2003; 25:38-45.
3. Kerner JA, Garcia-Careaga MG, Fisher AA, et al. Treatment of catheter occlusion in pediatric patients. J Parenter Enteral Nutr 2006 30(suppl 1):S73-S81.
4. Terrill KR, Lemons RS, Goldsby RE. Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer. J Pediatr Hematol Oncol 2003; 25:864-867.
5. Kellerman S, Chan J, Jarvis W. Use of urokinase in pediatric hematology/oncology patients. Am J Infect Control 1998; 26:502-6.
6. Jacobs BR, Haygood M, Hingl J. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children. J Pediatr 2001; 139:593-596.
7. US Food and Drug Administration Med Watch. Important drug warning: safety information regarding use of Abbokinase (Urokinase). Available at: http://www.fda.gov/cder/biologics/ltr/abb012599.pdf. Accessed January 3, 2006.
8. Cathflo Activase (alteplase) [prescribing information]. South San Francisco, CA: Genentech, Inc. Available at: http://www.gene.com/gene/products/ information/cardiovascular/cathfloactivase/insert.jsp. Accessed January 3, 2006.
9. Ponec D, Irwin D, Haire WD, et al. Recombinant tissue plasminogen activator (Alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial. J Vasc Interv Radiol 2001; 12:951-955.
10. Deitcher SR, Fesen MR, Kiproff PM, et al. Safety and efficacy of alteplase for restoring function in occluded central venous catheters. J Clin Oncol 2002; 20:317-324.
11. US Food and Drug Administration. Label and approval history, Cathflo Activase (alteplase). Supplement 5003. Available at: http://www.accessdata.fda. gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. Label_ApprovalHistory#apphist. Accessed January 3, 2006.
12. Collett D. Modeling binary data. London: Chapman and Hall, 1991.
13. Collen D, Lijnen HR. Fibrinolysis and the control of hemostasis. In: Stamatoyannopoulos G, Nienhui AW, Majerus PW, et al eds. The molecular basis of blood diseases. 2nd ed. Philadelphia: WB Saunders, 1994; 662-668.
14. Bamgbola OF, del Rio M, Kaskel FJ, et al. Recombinant tissue plasminogen activator infusion for hemodialysis catheter clearance. Pediatr Nephrol 2005; 20:989-993.
15. Weck S, Cheung S, Hiraoka-Sutow M, et al. Alteplase as a catheter locking solution: in vitro evaluation of biochemical stability and antimicrobial properties. J Vasc Interv Radiol 2005; 16:379-383.